CO6140062A2 - Anticuerpos anti-trop-2 humanizados y quiméricos que median citotoxicidad de celulas cancerosas - Google Patents

Anticuerpos anti-trop-2 humanizados y quiméricos que median citotoxicidad de celulas cancerosas

Info

Publication number
CO6140062A2
CO6140062A2 CO09135218A CO09135218A CO6140062A2 CO 6140062 A2 CO6140062 A2 CO 6140062A2 CO 09135218 A CO09135218 A CO 09135218A CO 09135218 A CO09135218 A CO 09135218A CO 6140062 A2 CO6140062 A2 CO 6140062A2
Authority
CO
Colombia
Prior art keywords
cdmab
monoclonal antibody
ovary
prostate
mammal
Prior art date
Application number
CO09135218A
Other languages
English (en)
Inventor
David S F Young
Helen P Findlay
Alison L Ferry
Luis A G Dacruz
Susan E Hahn
Original Assignee
Hofmann La Roche Ag F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hofmann La Roche Ag F filed Critical Hofmann La Roche Ag F
Publication of CO6140062A2 publication Critical patent/CO6140062A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

1.- Un método de reducción de un tumor pancreático, de seno, próstata, ovario o colon humano en un mamífero, caracterizado porque el tumor pancreático, de seno, próstata, ovario o colon humano expresa al menos un epítopo de un antígeno que se une específicamente al anticuerpo monoclonal aislado producido por la línea de células de hibridoma depositada en la IDAC con el número de registro 141205-05 o un CDMAB del mismo, CDMAB con capacidad para inhibir competitivamente la unión del anticuerpo rnonoclonal aislado a su antígeno objetivo, y que comprende administrar al mamífero el anticuerpo monoclonal o CDMAB del mismo en una cantidad efectiva para dar como resultado una reducción de la carga tumoral de páncreas, seno, próstata, ovario o colon del mamífero.2.- El método de conformidad con la reivindicación 1, caracterizado porque el anticuerpo monoclonal aislado es conjugado a una porción citotóxica. 3.- El método de conformidad con la reivindicación 2, caracterizado porqué la porción citotóxica es un isótopo radioactivo.4.- El método de conformidad con la reivindicación 1, caracterizado porque el anticuerpo monoclonal aislado o CDMAB del mismo activa complemento.
CO09135218A 2007-05-30 2009-11-26 Anticuerpos anti-trop-2 humanizados y quiméricos que median citotoxicidad de celulas cancerosas CO6140062A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/807,837 US20080131428A1 (en) 2006-02-24 2007-05-30 Cytotoxicity mediation of cells evidencing surface expression of TROP-2

Publications (1)

Publication Number Publication Date
CO6140062A2 true CO6140062A2 (es) 2010-03-19

Family

ID=39476049

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09135218A CO6140062A2 (es) 2007-05-30 2009-11-26 Anticuerpos anti-trop-2 humanizados y quiméricos que median citotoxicidad de celulas cancerosas

Country Status (15)

Country Link
US (1) US20080131428A1 (es)
EP (1) EP2155791A4 (es)
JP (1) JP2010528056A (es)
KR (1) KR20100003366A (es)
CN (1) CN101679526A (es)
AU (1) AU2008255528A1 (es)
CA (1) CA2687586A1 (es)
CO (1) CO6140062A2 (es)
CR (1) CR11127A (es)
EC (1) ECSP099770A (es)
IL (1) IL202092A0 (es)
MA (1) MA31393B1 (es)
MX (1) MX2009012732A (es)
WO (1) WO2008144891A1 (es)
ZA (1) ZA200908346B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
AU2002246632B2 (en) * 2000-12-08 2007-04-05 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line and its use for producing an antibody
US9249229B2 (en) * 2000-12-08 2016-02-02 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7408041B2 (en) * 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2007084321A2 (en) * 2006-01-12 2007-07-26 Alexion Pharmaceuticals, Inc. Antibodies to ox-2/cd200 and uses thereof
WO2007149586A2 (en) * 2006-06-22 2007-12-27 Vaccinex, Inc. Anti-c35 antibodies for treating cancer
MX2009006277A (es) * 2006-12-14 2009-07-24 Medarex Inc Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
KR20100036362A (ko) * 2007-07-25 2010-04-07 알렉시온 파마슈티칼스, 인코포레이티드 자가면역 질환 치료 방법 및 조성물
ES2611032T3 (es) * 2009-02-05 2017-05-04 Oncoxx Biotech S.R.L. Anticuerpos monoclonales anti-Trop-2 y sus usos en el tratamiento y diagnóstico de tumores
SG185583A1 (en) 2010-05-17 2012-12-28 Livtech Inc Anti-human trop-2 antibody having antitumor activity in vivo
EP2594589A1 (en) * 2010-06-10 2013-05-22 Sapporo Medical University ANTI-Trop-2 ANTIBODY
CN108117586A (zh) 2010-08-10 2018-06-05 洛桑聚合联合学院 红细胞结合性治疗剂
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
KR101979208B1 (ko) * 2011-08-04 2019-05-16 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
AU2012335205A1 (en) * 2011-11-11 2014-05-29 Rinat Neuroscience Corp. Antibodies specific for Trop-2 and their uses
US9427464B2 (en) * 2011-11-22 2016-08-30 Chiome Bioscience Inc. Anti-human TROP-2 antibody having an antitumor activity in vivo
US20140357577A1 (en) * 2011-12-19 2014-12-04 Janssen R&D Limited HIV Membrane Fusion Inhibitors
ITCH20120008A1 (it) * 2012-05-16 2013-11-17 Saverio Alberti Uso di trop-2 come marcatore predittivo di risposta a terapia anti-tumorale basata su inibitori di cd9, akt e vie di segnale collegate
KR102535900B1 (ko) 2013-12-25 2023-05-26 다이이찌 산쿄 가부시키가이샤 항 trop2 항체-약물 컨쥬게이트
SG10201800210TA (en) 2014-01-31 2018-02-27 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
JP6744227B2 (ja) 2014-02-21 2020-08-19 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） 糖標的化治療剤
CA2968330A1 (en) * 2014-12-04 2016-06-09 Abruzzo Theranostic S.R.L. Humanized anti-trop-2 monoclonal antibodies and uses thereof
EP4180455A1 (en) 2015-06-29 2023-05-17 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
CN104974988B (zh) * 2015-07-31 2016-08-24 南京麦科林生物医药科技有限公司 抗胰腺癌单克隆抗体及其应用
EP3518953A4 (en) * 2016-09-29 2020-10-28 Aebi Ltd. THERAPEUTIC MULTI-TARGETING CONSTRUCTS AND THEIR USES
AU2017377233A1 (en) 2016-12-12 2019-06-13 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
AU2018210081A1 (en) 2017-01-17 2019-08-08 Daiichi Sankyo Company, Limited Anti-GPR20 antibody and anti-GPR20 antibody-drug conjugate
TW202330036A (zh) 2017-05-15 2023-08-01 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance
CN117838880A (zh) 2017-08-31 2024-04-09 第一三共株式会社 制备抗体-药物缀合物的新方法
SG11202000997YA (en) 2017-08-31 2020-03-30 Daiichi Sankyo Co Ltd Improved method for producing antibody-drug conjugate
US11761963B2 (en) 2017-09-27 2023-09-19 Alexion Pharmaceuticals, Inc. Biomarker signature for predicting tumor response to anti-CD200 therapy
BR112020007321A2 (pt) * 2017-10-20 2020-09-29 F. Hoffmann-La Roche Ag conjugado de anticorpo, uso, uso de um marcador isotópico estável e kit
DK3794042T3 (da) 2018-05-18 2024-04-15 Daiichi Sankyo Co Ltd Anti-muc1-exatecet-antistof-lægemiddelkonjugat
US20210340628A1 (en) 2018-08-23 2021-11-04 Daiichi Sankyo Company, Limited Sensitivity marker for antibody-drug conjugate
EP3876998A1 (en) 2018-11-05 2021-09-15 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing trop-2
CN112243443B (zh) * 2019-05-10 2023-03-17 江苏豪森药业集团有限公司 抗trop-2抗体、其抗原结合片段及其医药用途
BR112021023901A2 (pt) 2019-05-29 2022-01-18 Daiichi Sankyo Co Ltd Conjugado anticorpo-fármaco anti-trop2, composição farmacêutica, método para tratar ou prevenir câncer, e, uso de um conjugado anticorpo-fármaco anti-trop2 na fabricação de um fármaco para o tratamento ou prevenção do câncer
WO2021027851A1 (zh) * 2019-08-12 2021-02-18 凯惠科技发展(上海)有限公司 一种trop2抗体及其制备方法、其偶联物和应用
US20230293716A1 (en) 2020-05-08 2023-09-21 Bolt Biotherapeutics, Inc. Elastase-substrate, peptide linker immunoconjugates, and uses thereof
AU2021326516A1 (en) 2020-08-13 2023-04-13 Bolt Biotherapeutics, Inc. Pyrazoloazepine immunoconjugates, and uses thereof
WO2022204536A1 (en) 2021-03-26 2022-09-29 Bolt Biotherapeutics, Inc. 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
IL306114A (en) 2021-03-26 2023-11-01 Bolt Biotherapeutics Inc 2-amino-4-carboxamide-benzazepine immunoconjugates and uses thereof
CA3234604A1 (en) 2021-10-29 2023-05-04 Shelley Erin ACKERMAN Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof
WO2023180485A1 (en) 2022-03-23 2023-09-28 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing trop-2

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001501801A (ja) * 1995-10-19 2001-02-13 ブリストル−マイヤーズ スクイッブ カンパニー モノクローナル抗体ｂｒ１１０およびその使用
CN100360567C (zh) * 2002-03-01 2008-01-09 免疫医疗公司 Rs7抗体
CA2643063A1 (en) * 2006-02-24 2007-08-30 Arius Research, Inc. Cancerous disease modifying antibody 141205-02
US7420041B2 (en) * 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2

Also Published As

Publication number Publication date
EP2155791A1 (en) 2010-02-24
CR11127A (es) 2009-12-29
KR20100003366A (ko) 2010-01-08
WO2008144891A1 (en) 2008-12-04
US20080131428A1 (en) 2008-06-05
MX2009012732A (es) 2009-12-10
JP2010528056A (ja) 2010-08-19
MA31393B1 (fr) 2010-05-03
CA2687586A1 (en) 2008-12-04
EP2155791A4 (en) 2010-09-22
IL202092A0 (en) 2010-06-16
AU2008255528A1 (en) 2008-12-04
CN101679526A (zh) 2010-03-24
ZA200908346B (en) 2010-08-25
ECSP099770A (es) 2009-12-28

Similar Documents

Publication Publication Date Title
CO6140062A2 (es) Anticuerpos anti-trop-2 humanizados y quiméricos que median citotoxicidad de celulas cancerosas
CO6241160A2 (es) Anticuerpos anti-cd44 quiméricos y humanizados que median la citotoxicidad de celulas de cancer
CO2022013599A2 (es) Anticuerpos anti-ccr8 para el tratamiento del cáncer
CL2017001580A1 (es) Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped.
JP2016116536A5 (es)
JP2013517487A5 (es)
MX2021014094A (es) Conjugados de anticuerpo-farmaco inhibidores de mcl-1 y sus metodos de uso.
ECSP12012138A (es) Anticuerpo monoclonico anti-cd44 que liga el carcinoma escamocelular de cabeza y cuello
AR054254A1 (es) Terapia adyuvante con trastuzumab (herceptin registrado)
EA201100779A1 (ru) Композиции антител к cxcr1 и способы их применения
MX2020008445A (es) Metodos para tratar el cancer con anticuerpos anti-pd-1.
AR050642A1 (es) Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/ calicheamicina
EA201490957A1 (ru) Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела
De Lorenzo et al. Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine
SI2631248T1 (en) Treatment of tumors using a specific antibody to L1
RU2009131840A (ru) Антитела, модифицирующие раковые заболевания
Wang et al. A novel 5T4-targeting antibody-drug conjugate H6-DM4 exhibits potent therapeutic efficacy in gastrointestinal tumor xenograft models
AR081321A1 (es) N-cadherina: un blanco para el diagnostico y la terapia del cancer
MX2021003673A (es) Anticuerpos anti-vsig4 humano y usos de los mismos.
RU2009104624A (ru) Антитела, модифицирующие раковые заболевания
RU2009131838A (ru) Антитела, модифицирующие раковые заболевания
MX2022005949A (es) Anticuerpos anti-ror-2 y metodos de uso.
EA202192587A1 (ru) Антитела к cd73, антитела к pd-l1 и химиотерапия для лечения опухолей
MX2009001014A (es) Mediacion de citotoxicidad de celulas que evidencian expresion de cd63 en superficie.
PE20091406A1 (es) Anticuerpos modificadores de enfermedades cancerosas